Background
The metabolic response to critical illness and the role of nutrition therapy
Guidelines for nutrition therapy in critical illness
Guideline | Basis of recommendation | Energy requirements | Protein requirements | Commencement of ENa | Commencement of PN |
---|---|---|---|---|---|
ASPEN/SCCM (2016) | Observational studies, RCTs, and consensus opinion from topic experts | Use IC (quality: very low) In the absence of IC use 25–30 kcal/kg/day (EC) Obesity: hypocaloric nutrition, 65-70% measured requirements by IC. If no IC, BMI 30–50 = 11–14 kcal/kg ABW/day; BMI > 50 = 22–25 kcal/kg IBW/day (EC) | 1.2–2 g/kg/day (quality: very low) Obesity: high protein, BMI 30–40 = 2.0 g/kg IBW/day; BMI ≥ 40 = up to 2.5 g/kg IBW/day (EC) | Early EN (24–48 h) (quality: very low) Patients at low nutrition risk, well-nourished, and/or with low disease severity do not require specialised nutrition therapy over the first week in ICU (EC) Patients at high nutrition risk or severely malnourished, EN should advance to goal as quickly as tolerated over 24–48 h in (while monitoring for refeeding) (quality: very low) | Exclusive PN (when oral intake or EN contraindicated) for patients at low nutrition risk, withhold for the first 7 days (quality: very low) For patients at high nutrition risk or severely malnourished start PN as soon as possible (EC) Supplemental PNb should be considered after 7–10 days if unable to meet > 60% of energy and protein requirements by EN (quality: moderate) |
Canadian Clinical Practice Guidelines (2015) | RCTs and consensus opinion from topic experts | Nil | Nil | Early EN (within 24–48 h) (based on 16 level 2 studiesc) | Exclusive PN (when oral intake or EN contraindicated) should be considered early in nutritionally high-risk patients (based on 6 level 2 studiesc) For patients who are not malnourished, are tolerating some EN, or when PN is indicated for <10 days, low dose PN should be considered (based on 4 level 2 studiesc) Supplemental PNb should be assessed on case-by-case basis (based on 1 level 1 study and 7 level 2 studiesc) |
ESICM clinical practice guidelines (2017) | Observational studies, RCTs, and consensus opinion from topic experts | Nil | Nil | Early EN should be prescribed rather than delaying EN (low-quality evidence) | Nil |
ESPEN (2019) | Observational studies, RCTs, and consensus opinion from topic experts | Use IC (grade Bd) In the absence of IC use VO2 or VCO2 predictive equations (grade 0d) Obesity: if no IC, 20–25 kcal/kg ABW/day (grade 0d) | 1.3 g/kg/day delivered progressively (grade 0d) Obesity: 1.3 g/kg ABW/day (grade 0d) | Early EN (within 48 h) (grade Ad) Hypocaloric nutrition (< 70% of EE) in the early acute phase (ICU day 1–3) (grade Bd) If using IC—isocaloric nutrition (80–100% EE) can be progressively implemented after day 3 (grade 0d) If using predictive equations—hypocaloric nutrition (< 70% of EE) for the first week (grade Bd) | Exclusive PN (when oral intake or EN contraindicated) within 3–7 days (grade Bd) For severely malnourished patients, consider early and progressive PN (grade 0d) Supplemental PNb should be considered on a case-by-case basis (grade 0d) |
Energy in critical illness
Equation factors | Patient and system factors |
---|---|
• Sample size of the original equation • The characteristics of the original development population (including age, body composition, and disease state) • The population characteristics in which the equation is used • The addition of commonly used ‘injury’ or ‘stress’ factors • Using an adjusted body weight with the equation | • Individual patient heterogeneity in the metabolic response to critical illness • Differing body composition (fat-free mass and fat mass) • Changes in medical management over time in elements that impact metabolism (like surgery, pain, and sedation practices) |
Estimating energy expenditure via VO2 and VCO2
Measuring energy expenditure in the critically ill—indirect calorimetry
Measurement or estimation of energy expenditure?
Protein in critical illness
Protein delivery and clinical outcomes
How much energy and protein do patients get in clinical practice?
What energy and protein targets should clinicians aim for?
Enteral nutrition
When to start?
How should EN be delivered?
EN delivery—an ongoing challenge
Strategy | Evidenced-based feeding protocol | GRV (minimum 500 ml cut-off) | Appropriate and timely use of prokinetics for EN intolerance | Post-pyloric tubes for EN intolerance |
---|---|---|---|---|
ASPEN/SCCM (2016) | Use an EN protocol (designed and implemented to increase the overall percentage of goal energy delivered) (quality: moderate to high) | Do not use GRVs as part of routine care to monitor ICU patients on EN If GRVs are used, use 500ml cut-off (quality: low) | Use metoclopramide or erythromycin where indicated (quality: low) | Nil |
Canadian Clinical Practice Guidelines (2015) | Use an EN protocol (that details strategies to improve delivery of EN) (based on 2 level 2 studies and 3 cluster RCTsa) | Use GRV of 250–500 ml every 4–6 h (based on 3 level 2 studiesa) | Use metoclopramide where indicated (based on 1 level 1 study and 5 level 2 studiesa) | Use post-pyloric tubes for patients at high risk for intolerance to EN or aspiration (based on 16 level 2 studiesa) |
ESPEN (2019) | Nil | EN should only be delayed when GRV is > 500 ml/6 h (grade 0b) | Use IV erythromycin as a first line therapy (grade of recommendation Bb) or use IV metaclopramide or combination therapy (grade 0b) Alternatively, combination therapy (IV metoclopramide and erythromycin) (grade 0b) | Use post-pyloric feeding for EN intolerance not resolved with prokinetics (grade Bb) |
Parenteral nutrition
When to start?
Body composition analysis
Method | Measurement | Details | Benefits | Limitations |
---|---|---|---|---|
CT image analysis at the abdominal (L3) area | • Muscle CSA (cm2) • Muscle quality (density) (Hounsfield units) | • Specialised software can be used to measure muscle area and density using a CT slice at L3 • Quantification of muscle CSA at L3 is highly correlated to whole body muscle (using scans performed for clinical purposes) | • Provides specific and precise results • Published cut-off values to identify patients with lower than normal muscularity | • Limited for use in patients who have had a CT at L3 area • Specialist training and time required for analysis |
Bioimpedance analysis (multi-frequency or spectroscopy) | • Fat-free mass (kg) • Phase angle (50 kHz) | • Involves application of a weak current at differing frequencies, through electrodes placed on the hands and feet • Total body water, percentage body fat, and fat-free mass are estimated via regression equations (with assumed constants for estimating intra- and extracellular water) • Raw data such as phase angle (which is independent of weight and related to cellular health) may be a predictor of outcome in critically ill populations | • Easy and quick to use • Safe (no radiation involved) | • Fat-free mass estimates are not likely to be reliable in critically ill patients who experience significant fluid shifts • Positioning (separation in limbs) and electrode placement may be challenging in some ICU patients |
Ultrasound | • Muscle thickness (cm) • Muscle CSA (cm2) • Muscle quality (echogenicity) | • Muscle thickness and CSA can be measured at different sites (i.e. quadriceps, upper arm) • Muscle quality can also be assessed using specialist software | • Readily available in most ICUs • Easy, safe, and quick to use | • No consensus on the ideal sites to predict whole body muscle or to monitor changes over time • Role of oedema on measurements is unclear • No widely accepted cut-points to identify patients with low muscularity |